8.2 Intracranial Hypertension and Brain Edema

Intracranial hypertension is a critical, life-threatening complication of severe neurological injuries, including traumatic brain injury (TBI), aneurysmal subarachnoid hemorrhage (aSAH), large hemispheric ischemic strokes (e.g., malignant middle cerebral artery syndrome), large intracerebral hemorrhages (ICH), and fulminant central nervous system infections. Undetected or inadequately managed intracranial hypertension leads directly to secondary brain injury, irreversible brain tissue ischemia, herniation syndromes, and brain death.

Pathophysiology and the Monro-Kellie Doctrine

The skull is a rigid, non-distensible bony vault with a fixed volume. Under normal physiological conditions, the total intracranial volume (~1,500 to 1,900 mL) is divided among three incompressible components:

1. Brain Parenchyma: Comprises approximately 80% of the volume.
2. Cerebrospinal Fluid (CSF): Comprises approximately 10% of the volume.
3. Intracranial Blood (Venous and Arterial): Comprises approximately 10% of the volume.

According to the Monro-Kellie Doctrine, the sum of these volumes is constant ($V_{\text{brain}} + V_{\text{CSF}} + V_{\text{blood}} = V_{\text{intracranial}}$). Consequently, an increase in the volume of any one of these components, or the introduction of a pathological space-occupying lesion (such as an epidural hematoma, tumor, or abscess), must be compensated by an equal reduction in the volume of the remaining components.

The primary compensatory mechanisms include the displacement of CSF from the ventricles and subarachnoid space into the spinal canal, and the extrusion of venous blood into the systemic circulation via the jugular veins. Once these compensatory pathways are fully exhausted, the intracranial compliance curve reaches its inflection point. At this stage, even minute additions of volume lead to exponential rises in intracranial pressure (ICP).

Cerebral Perfusion Pressure (CPP) and Autoregulation

Adequate blood flow to the brain is estimated by the Cerebral Perfusion Pressure (CPP), defined as the Mean Arterial Pressure (MAP) minus the Intracranial Pressure (ICP): $\text{CPP} = \text{MAP} - \text{ICP}$

Under normal conditions, cerebral blood flow (CBF) is held constant across a wide range of MAPs (typically 50 to 150 mmHg) through a process known as cerebral autoregulation. In the injured brain, autoregulation is frequently impaired or lost entirely, making CBF linearly dependent on CPP.

• Normal ICP Range: 5 to 15 mmHg in adults.
• ICP Treatment Threshold: Treatment is indicated when the ICP rises above 22 mmHg for greater than 5 minutes, as recommended by the Brain Trauma Foundation (BTF) guidelines.
• CPP Target Range: The BTF guidelines recommend maintaining a target CPP of 60 to 70 mmHg.
  • CPP < 60 mmHg: Leads to inadequate cerebral perfusion, worsening tissue hypoxia, and ischemic infarction.
  • CPP > 70 mmHg: Often requires aggressive administration of intravenous fluids and vasopressors (such as norepinephrine), which increases the risk of systemic complications, most notably Acute Respiratory Distress Syndrome (ARDS) via capillary leak, as well as myocardial ischemia.

ICP Monitoring Indications

Per the BTF guidelines, ICP monitoring is indicated in patients with severe traumatic brain injury (defined as a Glasgow Coma Scale [GCS] score of 3 to 8 after cardiopulmonary resuscitation) who also present with an abnormal head CT scan showing pathology such as hematomas, contusions, swelling, herniation, or compressed basal cisterns.

Monitoring is also indicated in severe TBI patients with a normal head CT scan if they present with two or more of the following risk factors at admission:

1. Age greater than 40 years.
2. Unilateral or bilateral motor posturing (decorticate or decerebrate).
3. Systolic blood pressure (SBP) less than 90 mmHg.

---

Tiered Pharmacological and Clinical Management of Elevated ICP

When ICP exceeds the 22 mmHg threshold, clinical guidelines recommend a stepwise, tiered approach to manage the pressure and preserve CPP.

Tier 1: Physiological Optimization and Baseline Interventions

• Venous Drainage: Elevate the head of the bed to 30 to 45 degrees and maintain the head in a neutral, midline position. This facilitates gravity-assisted venous outflow from the jugular veins. Ensure that endotracheal tube ties or cervical collars are not excessively tight, which can compress the jugular veins and increase ICP.
• Analgesia and Sedation: Agitation, pain, and ventilator dyssynchrony elevate intrathoracic and intra-abdominal pressures, which impede venous return and raise ICP. Continuous infusions of highly lipophilic agents, such as fentanyl and propofol, are preferred to allow rapid titration and intermittent sedation vacations for neurological examinations.
• Normothermia: Fever increases the cerebral metabolic rate of oxygen ($\text{CMRO}_2$) by approximately 5% to 10% per degree Celsius. This metabolic surge triggers compensatory vasodilation, increasing cerebral blood volume and ICP. Antipyretics and targeted temperature management (TTM) using surface or intravascular cooling devices must be deployed to maintain strict normothermia ($36.0^\circ\text{C}$ to $37.5^\circ\text{C}$). Prevent shivering aggressively (e.g., using buspirone, magnesium, or neuromuscular blockers) as shivering dramatically increases ICP.
• External Ventricular Drain (EVD) CSF Drainage: The placement of an EVD (ventriculostomy) is the gold standard for both measuring ICP and therapeutically draining CSF. When ICP exceeds the threshold, the EVD stopcock can be opened to drain a small volume of CSF (typically 3 to 5 mL), which provides immediate mechanical relief due to the steep pressure-volume curve.

Tier 2: Hyperosmolar Therapy

Hyperosmolar therapy works by establishing an osmotic gradient across the blood-brain barrier (BBB), drawing interstitial water out of the edematous brain parenchyma and into the intravascular space, where it is cleared systemically. For this to work, the BBB must be relatively intact.

Mannitol

• Pharmacology and Action: Mannitol is an osmotic diuretic. It has a dual mechanism of action. Initially, it exerts a rheological (plasma-expanding) effect: it decreases blood viscosity, which enhances microvascular blood flow and oxygen delivery. This prompts a compensatory autoregulatory vasoconstriction of cerebral pial arterioles, rapidly decreasing cerebral blood volume and ICP within 5 to 15 minutes. Subsequently, the osmotic effect peaks at 30 to 45 minutes, drawing water out of the brain parenchyma.
• Dosing: Dosed at 0.25 to 1 g/kg administered as an intravenous bolus over 20 to 30 minutes. It is typically prepared as a 20% solution ($20\text{ g}/100\text{ mL}$). It must be administered through an inline filter ($0.22\text{ micron}$) because mannitol solutions can crystallize at room temperature.
• Monitoring and Toxicity: Mannitol induces profound renal diuresis, which can result in intravascular volume depletion, hypotension, and a subsequent drop in CPP. To prevent acute kidney injury (AKI), serum osmolality and the osmolar gap must be monitored closely: $\text{Osmolar Gap} = \text{Measured Osmolality} - \text{Calculated Osmolality}$ $\text{Calculated Osmolality} = 2[\text{Na}^+] + \frac{\text{Glucose}}{18} + \frac{\text{BUN}}{2.8}$ Traditionally, mannitol is held if the serum osmolality exceeds 320 mOsm/kg. However, the osmolar gap is a more accurate indicator of mannitol accumulation and renal clearance. A target osmolar gap of < 20 mOsm/kg should be maintained. Accumulation of mannitol in the renal tubules leads to renal vasoconstriction and acute tubular necrosis. Furthermore, if mannitol accumulates in the brain tissue (which occurs with prolonged exposure or a damaged BBB), it can reverse the osmotic gradient, drawing water into the parenchyma and causing rebound intracranial hypertension.

Hypertonic Saline (HTS)

• Pharmacology and Action: Hypertonic saline acts purely through an osmotic gradient, drawing water into the intravascular space without inducing a systemic diuretic effect. This helps preserve intravascular volume and hemodynamic stability, making HTS the preferred agent in patients who are hypotensive or volume-depleted. Additionally, HTS has mild anti-inflammatory and neuroprotective properties.
• Concentrations and Dosing:
  • 3% HTS: Frequently administered as an intravenous bolus of 250 to 500 mL over 15 to 30 minutes, or as a continuous infusion starting at 30 to 50 mL/hr.
  • 23.4% HTS: Reserved as a rescue 'bullet' bolus for acute herniation or refractory ICP spikes. Administered as 30 mL over 10 to 20 minutes.
• Administration Requirements: Due to high osmolarity (3% HTS is ~1,026 mOsm/L; 23.4% HTS is ~8,008 mOsm/L), concentrations greater than 3% must be administered via a central venous catheter to prevent severe chemical phlebitis, local tissue necrosis, and extravasation injury. While 3% HTS is ideally given centrally, it can be administered via a large-bore peripheral intravenous line in emergent situations for short durations.
• Monitoring and Risks:
  • Sodium Targets: Serum sodium levels must be monitored every 4 to 6 hours, with a target range of 145 to 155 mEq/L (and serum osmolality kept < 360 mOsm/kg).
  • Osmotic Demyelination Syndrome (ODS): Also known as central pontine myelinolysis. The rapid correction of chronic hyponatremia is associated with ODS. While this risk is lower in patients who are normonatremic at baseline, care must still be taken to avoid overly rapid fluctuations in serum sodium.
  • Hyperchloremic Metabolic Acidosis: Infusions of large volumes of sodium chloride deliver a heavy chloride load, which can induce hyperchloremic metabolic acidosis. This can be mitigated by utilizing a customized sodium mixture containing sodium acetate (which is metabolized to bicarbonate) alongside sodium chloride.
  • Rebound ICP: Similar to mannitol, rapid discontinuation of HTS can cause a rebound rise in ICP as the brain adapts to the hyperosmolar state.

Tier 3: Advanced and Rescue Interventions

When hyperosmolar therapy fails to control ICP, advanced and highly invasive measures must be initiated.

• Mild Hyperventilation: Hyperventilation lowers the partial pressure of arterial carbon dioxide ($\text{PaCO}_2$). Carbon dioxide is a potent regulator of cerebral vasomotor tone; hypocapnia induces cerebral vasoconstriction, which rapidly reduces cerebral blood volume and ICP.
  • Target PaCO2: 30 to 35 mmHg.
  • Clinical Warning: This intervention must be used only as a short-term, temporary bridge (e.g., during acute herniation while preparing for surgical decompression). Prolonged hyperventilation causes sustained vasoconstriction, which can critically reduce cerebral blood flow and induce tissue ischemia. This is especially dangerous during the first 24 to 48 hours post-injury when CBF is already compromised. If hyperventilation is sustained, monitoring of brain tissue oxygen tension ($\text{PbtO}_2$) or jugular venous oxygen saturation ($\text{SjO}_2$) is highly recommended.
• Barbiturate Coma (Pentobarbital): Barbiturates are potent central nervous system depressants that suppress cerebral metabolic activity.
  • Mechanism: Pentobarbital decreases metabolic demand, which leads to coupled cerebral vasoconstriction, reducing CBF, cerebral blood volume, and ICP.
  • Dosing: Administer a loading dose of 5 to 20 mg/kg IV over 10 to 60 minutes, followed by a maintenance infusion of 1 to 4 mg/kg/hr.
  • EEG Target: The infusion must be titrated under continuous electroencephalography (cEEG) monitoring to achieve a target of burst suppression (typically defined as 3 to 5 bursts per minute, or 10 to 15 seconds of flatline suppression between bursts).
  • Safety and Monitoring: Barbiturate therapy is associated with profound systemic adverse effects. It causes direct myocardial depression and venodilation, frequently resulting in severe, refractory hypotension. Continuous arterial line and advanced hemodynamic monitoring are mandatory. Vasopressor support (commonly norepinephrine) is almost always required to maintain the target CPP. Pentobarbital also causes paralytic ileus, severe immunosuppression (predisposing patients to ventilator-associated pneumonia), and hypokalemia (which can shift to rebound hyperkalemia when the infusion is discontinued).
• Therapeutic Hypothermia: Cooling the body to 32.0°C to 35.0°C reduces $\text{CMRO}_2$ (approximately 6% to 8% decrease for every 1°C drop) and attenuates the neuroinflammatory cascade.
  • Clinical Efficacy: The Eurotherm3235 trial demonstrated that early therapeutic hypothermia in patients with TBI did not improve functional outcomes and was associated with increased adverse events. Therefore, therapeutic hypothermia is strictly reserved as a late-tier rescue therapy for refractory ICP.
  • Adverse Effects: Complications include severe shivering, cardiac arrhythmias (especially brain-injuring bradycardia and QTc prolongation), electrolyte shifts (hypokalemia during cooling, hyperkalemia during rewarming), coagulopathy, and increased infection risk. Rewarming must be performed very slowly (typically $0.1^\circ\text{C}$ to $0.25^\circ\text{C}$ per hour) to avoid rapid shifts in potassium and rebound intracranial hypertension.

Surgical Decompression (Decompressive Craniectomy)

Decompressive craniectomy involves the surgical removal of a large section of the skull (with incision of the underlying dura mater) to convert the rigid intracranial vault into an open system, allowing the swollen brain to expand outward.

• Indications: Indicated for refractory intracranial hypertension unresponsive to medical therapy in patients with severe TBI, large hemispheric ischemic strokes (malignant MCA infarction), or large space-occupying lobar hemorrhages.
• Clinical Trials and Outcomes:
  • DECRA Trial: Evaluated early, neuro-intensive care-tier decompressive craniectomy for moderate ICP elevations ($> 20\text{ mmHg}$ for $> 15\text{ minutes}$). Craniectomy decreased ICP and shortened ICU length of stay but resulted in worse functional outcomes (increased rates of vegetative state or severe disability) compared to standard medical care.
  • RESCUEicp Trial: Evaluated decompressive craniectomy as a late-tier rescue for refractory, severe ICP elevations ($> 25\text{ mmHg}$ for $> 1\text{ hour}$). In this trial, craniectomy significantly reduced mortality at 6 and 12 months. However, the reduction in mortality was accompanied by an increase in patients surviving in a vegetative state or with severe disability, though a portion of patients did achieve functional independence.